2-[2-[[(2-Methylpropan-2-yl)oxycarbonylamino]methyl]-1,3-thiazol-4-yl]-1,3-oxazole-4-carboxylic acid | 182120-95-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[2-[[(2-Methylpropan-2-yl)oxycarbonylamino]methyl]-1,3-thiazol-4-yl]-1,3-oxazole-4-carboxylic acid
• 英文别名: 2-[2-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]-1,3-thiazol-4-yl]-1,3-oxazole-4-carboxylic acid
• CAS: 182120-95-2
• 化学式: C₁₃H₁₅N₃O₅S
• 分子量: 325.345
• InChiKey: GIIAIEJGXUERMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  143
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-[2-[[(2-Methylpropan-2-yl)oxycarbonylamino]methyl]-1,3-thiazol-4-yl]-1,3-oxazole-4-carboxylic acid 在 sodium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 12.75h， 生成 Fmoc-Gly-Cys(Thz)-Ser(Oxz)-OH
  参考文献：
  名称：

  Videnov, Georgi; Kaiser, Dietmar; Kempter, Christoph, Angewandte Chemie, 1996, vol. 108, # 13/14, p. 1604 - 1607

  摘要：

  DOI：
• 作为产物：
  描述：

  2-((叔丁氧羰基氨基)甲基)噻唑-4-甲酸乙酯 在 N-甲基吗啉 、 甲醇 、 水 、 N,N-二异丙基乙胺 、 sodium hydroxide 、 lithium hydroxide 、 [双(2-甲氧基乙基)胺]三氟化硫 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 27.25h， 生成 2-[2-[[(2-Methylpropan-2-yl)oxycarbonylamino]methyl]-1,3-thiazol-4-yl]-1,3-oxazole-4-carboxylic acid
  参考文献：
  名称：

  Total Synthesis of Microcin B17 via a Fragment Condensation Approach

  摘要：

  The total synthesis of the 43 amino acid antibacterial peptide Microcin B17 (MccB17) is described. The natural product was synthesized via a convergent approach from a heterocycle-derived peptide and peptide thioester fragments prepared via Fmoc-strategy solid phase peptide synthesis (SPPS). Final assembly was achieved in an efficient manner using two Ag(I)-assisted peptide ligation reactions to afford MccB17 in excellent overall yield.

  DOI：

  10.1021/ol102916b

文献信息

• Microcin B17 Analogs And Methods For Their Preparation And Use
  申请人：Coquin Laurence

  公开号：US20080234132A1

  公开（公告）日：2008-09-25

  The present invention pertains to synthetic analogues of microcin B17 component units, methods of making and using these analogues, including, for example, as inhibitors of DNA gyrase. More particularly, the present invention pertains to compounds of the Formula wherein: W is independently: —H or a peptide group; Z is independently: —OH or a peptide group; wherein each peptide group, if present, is: an amino acid group and comprises exactly one amino acid, or: a poly(amino acid) group and comprises two or more amino acids; R N3 is independently: —H, C 1-6 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl, or C 3-6 cycloalkenyl, C 6-14 -carboaryl, C 5-14 heteroaryl, C 6-14 carboaryl-C 1-6 alkyl, C 5-14 heteroaryl-C 1-6 alkyl, and is optionally substituted; the circle represents a mono-heterocycle or a bis-heterocycle, wherein the heterocycle, or each of the two heterocycles, is a five membered ring having at least a first ring heteroatom that is N, and optionally a second ring heteroatom that is selected from N, O, and S; and the heterocycle, or each of the two heterocycles, is optionally substituted with one or more substituents; and pharmaceutically acceptable salts, amides, esters, solvates, and hydrates thereof. The present invention also pertains to uses of such compounds, for example, to inhibit DNA Gyrase activity in a cell and in methods of therapy, for example, to treat a disease or condition that is ameliorated by the inhibition of DNA Gyrase, such as a bacterial infection, cancer, etc.; as a herbicide; as a microbicide; as a bactericide; etc.

  本发明涉及微小肽B17组分单元的合成类似物，制备和使用这些类似物的方法，包括作为DNA酶抑制剂。更具体地说，本发明涉及以下式的化合物：其中：W独立地为：—H或肽基团；Z独立地为：—OH或肽基团；其中每个肽基团，如果存在，则为：氨基酸基团，包括恰好一个氨基酸，或：多肽（氨基酸）基团，包括两个或更多氨基酸；RN3独立地为：—H、C1-6烷基、C2-6烯基、C3-6环烷基或C3-6环烯基、C6-14芳基、C5-14杂芳基、C6-14芳基-C1-6烷基、C5-14杂芳基-C1-6烷基，并且可选地被取代；圆圈表示单杂环或双杂环，其中杂环或两个杂环中的每一个都是具有至少一个第一环杂原子的五元环，该原子是N，可选地，第二环杂原子是从N、O和S中选择的；并且该杂环或两个杂环可选地被一个或多个取代基取代；以及其药学上可接受的盐、酰胺、酯、溶剂化物和水合物。本发明还涉及这些化合物的用途，例如，在细胞中抑制DNA酶活性和治疗方法中使用，例如治疗通过抑制DNA酶改善的疾病或病况，如细菌感染、癌症等；作为除草剂；作为杀菌剂；作为杀菌剂等。
• Synthesis and Biological Characterization of the Histone Deacetylase Inhibitor Largazole and C7- Modified Analogues
  作者：José A. Souto、Esther Vaz、Ilaria Lepore、Ann-Christin Pöppler、Gianluigi Franci、Rosana Álvarez、Lucia Altucci、Ángel R. de Lera

  DOI：10.1021/jm100244y

  日期：2010.6.24

  Largazole 4a and analogues with modifications at the C7 position, as well as 2,4'-bithiazole 5a, have been synthesized using an acyclic cross-metathesis of the corresponding depsipeptide structures assembled by N-C6(O) or C15(O)-N lactam formation. Similar to the parent system 4a, the series of largazole depsipeptides 4b-d, but not 2,4'-bithiazole 5a, showed a marked inhibition of recombinant HDAC1 and selectivity over HDAC4, as well as strong pro-apoptotic effects on the NB4 leukemia cell line, but they failed to induce differentiation to mature granulocytes. Functional assays of the analogues correlated with the in vitro activities, as shown by increased H3 and a-tubulin acetylation levels and p21(WAF1/C1P1) up-regulation in NB4 cells. The activity of the natural product HDACi largazole 4a is not significantly altered by the presence of groups of different size (H, Et, Ph) at C7 on the dihydrothiazole ring.